Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260822 | 0.77 | PPARA (0.53) | KDM4EALDH1A1CNR2PPARACNR1 | |
| SCHEMBL27675855 | 0.74 | CNR2 (0.51) | KDM4EMAPK1L3MBTL1CNR2CNR1 | |
| SCHEMBL9147013 | 0.72 | TP53 (0.56) | ALDH1A1 | |
| SCHEMBL2839058 | 0.72 | CNR2 (0.52) | KDM4EMAPK1L3MBTL1ALDH1A1CNR2 | |
| SCHEMBL27675857 | 0.72 | CNR2 (0.48) | KDM4EMAPK1L3MBTL1CNR2CNR1 | |
| SCHEMBL2842661 | 0.70 | CNR2 (0.50) | KDM4EMAPK1L3MBTL1ALDH1A1CNR2 | |
| SCHEMBL2848554 | 0.70 | CNR2 (0.50) | KDM4EMAPK1L3MBTL1ALDH1A1CNR2 | |
| SCHEMBL2846352 | 0.70 | CNR2 (0.50) | KDM4EMAPK1L3MBTL1ALDH1A1CNR2 | |
| SCHEMBL2844258 | 0.70 | CNR2 (0.50) | L3MBTL1ALDH1A1CNR2CNR1LMNA | |
| SCHEMBL28783874 | 0.69 | KDM4E (0.60) | KDM4EALDH1A1CNR2CNR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8293778-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-10-23 | — | — | US | disclosed |
| EP-1773790-B1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20110207688-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DUNN JAMES PATRICK | 2011-08-25 | — | — | US | disclosed |
| CN-1993332-B | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2011-04-06 | — | — | CN | disclosed |
| US-7754919-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| US-7666891-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-7625897-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2007039463-A1 | NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| CN-1946680-A | Non-nucleoside reverse transcriptase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-04-11 | — | — | CN | disclosed |
| US-20070078128-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-05 | — | — | US | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-20060025462-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2006010545-A1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078128-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, HPRT1, RTF1 | KDM4E 1274/4885MAPK1 2467/4885L3MBTL1 1826/4885 |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | KDM4E 2322/4885MAPK1 2990/4885L3MBTL1 1092/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | KDM4E 2182/4885MAPK1 2295/4885L3MBTL1 984/4885 |
| US-20110207688-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | MAVS, IRF3, ZC3HAV1 | KDM4E 1894/4885MAPK1 2268/4885L3MBTL1 730/4885 |
| US-20060025462-A1 | Heterocyclic antiviral compounds | MAVS, IRF3, ZC3HAV1 | KDM4E 2391/4885MAPK1 1578/4885L3MBTL1 1159/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | KDM4E 1144/4885MAPK1 2180/4885L3MBTL1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.